NITRASE-color-horizontal.jpg
Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics
November 02, 2021 08:00 ET | Nitrase Therapeutics
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc. (formerly Nitrome Biosciences), a biopharmaceutical company deploying its unique NITROME platform to unlock the...
Nitrome_logo_2020.png
Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson
November 12, 2020 16:00 ET | Nitrome Biosciences
SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to...
Nitrome_logo_2020.png
Nitrome Biosciences Appoints Industry Veteran Perry Karsen as Executive Chairman of the Board of Directors
October 13, 2020 08:00 ET | Nitrome Biosciences
SAN FRANCISCO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to...